Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: July 28, 2023
Breast
cancer
is
one
of
the
most
diagnosed
solid
cancers
globally.
Extensive
research
has
been
going
on
for
decades
to
meet
challenges
treating
tumors
with
selective
compounds.
This
article
aims
summarize
therapeutic
agents
which
are
either
being
used
or
currently
under
approval
use
in
treatment
mitigation
breast
by
US
FDA,
date.
A
structured
search
bibliographic
databases
previously
published
peer-reviewed
papers
registered
molecules
was
explored
and
data
sorted
terms
various
categories
drugs
first
line/adjuvant
therapy
different
stages
cancer.
We
included
more
than
300
papers,
including
both
reviews
articles,
order
provide
readers
an
useful
comprehensive
information.
list
39
discussed
along
their
current
status,
dose
protocols,
mechanism
action,
pharmacokinetics,
possible
side
effects,
marketed
formulations.
Another
interesting
aspect
focusing
novel
formulations
these
clinical
trials
process
approval.
exhaustive
review
thus
shall
be
a
one-stop
solution
researchers
who
working
areas
formulation
development
drugs.
We
report
the
assembly
of
poly(ethylene
glycol)
nanoparticles
(PEG
NPs)
and
optimize
their
surface
chemistry
to
minimize
formation
protein
coronas
immunogenicity
for
improved
biodistribution.
PEG
NPs
cross-linked
with
disulfide
bonds
are
synthesized
utilizing
zeolitic
imidazolate
framework-8
as
templates,
which
subsequently
modified
molecules
different
end
groups
(carboxyl,
methoxy,
or
amino)
vary
chemistry.
Among
modifications,
amino
residual
carboxyl
form
a
pair
zwitterionic
structures
on
NPs,
adsorption
proteins
(e.g.,
immunoglobulin,
complement
proteins)
maximize
blood
circulation
time.
The
influence
preexisting
antibodies
in
mice
pharmacokinetics
is
negligible,
demonstrates
resistance
anti-PEG
inhibition
accelerated
clearance
phenomenon.
This
research
highlights
importance
PEGylated
design
delivery
systems
reveals
translational
potential
cancer
therapy.
Experimental Hematology and Oncology,
Journal Year:
2025,
Volume and Issue:
14(1)
Published: Jan. 31, 2025
Liposomes
and
lipid
nanoparticles
are
common
lipid-based
drug
delivery
systems
play
important
roles
in
cancer
treatment
vaccine
manufacture.
Although
significant
progress
has
been
made
with
these
nanocarriers
recent
years,
efficient
clinical
translation
of
active
targeted
liposomal
remains
extremely
challenging.
In
this
review,
we
focus
on
liposomes,
stimuli-responsive
strategy
combined
therapy
treatment.
We
also
summarize
advances
liposome
nanoparticle
applications
nucleic
acid
tumor
vaccination.
addition,
discuss
limitations
challenges
the
nanomaterials
make
recommendations
for
future
research
therapy.
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: Dec. 2, 2022
Bioorthogonal
chemistry
reactions
occur
in
physiological
conditions
without
interfering
with
normal
processes.
Through
metabolic
engineering,
bioorthogonal
groups
can
be
tagged
onto
cell
membranes,
which
selectively
attach
to
cargos
paired
via
reactions.
Due
its
simplicity,
high
efficiency,
and
specificity,
has
demonstrated
great
application
potential
drug
delivery.
On
the
one
hand,
improve
therapeutic
agent
delivery
target
sites,
overcoming
off-target
distribution.
other
nanoparticles
biomolecules
linked
membranes
by
reactions,
providing
approaches
developing
multi-functional
systems
(DDSs).
In
this
review,
we
first
describe
principle
of
labeling
cells
or
pathogenic
microorganisms
groups.
We
then
highlight
recent
breakthroughs
active
targeting
DDSs
tumors,
immune
systems,
bacteria
chemistry,
as
well
applications
functional
bio-inspired
(biomimetic
DDSs,
cell-based
bacteria-based
phage-based
DDSs)
hydrogels.
Finally,
discuss
difficulties
prospective
direction
expect
review
will
help
us
understand
latest
advances
development
using
inspire
innovative
smart
for
disease
treatment.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(11), P. 2620 - 2620
Published: Nov. 12, 2023
Colorectal
cancer
(CRC)
is
one
of
the
deadliest
malignancies
in
US,
ranking
fourth
after
lung,
prostate,
and
breast
cancers,
respectively,
general
populations.
It
continues
to
be
a
menace,
incidence
has
been
projected
more
than
double
by
2035,
especially
underdeveloped
countries.
This
review
seeks
provide
some
insights
into
disease
progression,
currently
available
treatment
options
their
challenges,
future
perspectives.
Searches
were
conducted
PubMed
search
engine
university’s
online
library.
The
keywords
“Colorectal
Cancer”
AND
“disease
process”
OR
mechanisms”
“Current
Treatment”
“Prospects”.
Selection
criteria
original
articles
published
primarily
during
period
2013
through
2023.
Abstracts,
books
documents,
reviews/systematic
reviews
filtered
out.
Of
over
490
thousand
returned,
only
about
800
met
preliminary
selection
criteria,
200
reviewed
detail,
but
191
final
criteria.
Fifty-one
other
used
due
cross-referencing.
Although
recently
considered
lifestyle,
CRC
appears
rising
countries
with
low,
low–medium,
medium
social
demographic
indices.
can
affect
all
parts
colon
rectum
fatal
poor
outcomes
when
it
right-sided.
progression
usually
takes
between
7–10
years
asymptomatic,
making
early
detection
diagnosis
difficult.
tumor
microenvironment
made
up
different
types
cells
interacting
each
promote
growth
proliferation
cells.
Significant
advancement
colorectal
cancer.
Notable
approaches
include
surgery,
chemotherapy,
radiation
therapy,
cryotherapy.
Chemotherapy,
including
5-fluorouracil,
irinotecan,
oxaliplatin,
leucovorin,
plays
significant
role
management
that
diagnosed
at
advanced
stages.
Two
classes
monoclonal
antibody
therapies
have
approved
FDA
for
cancer:
vascular
endothelial
factor
(VEGF)
inhibitor,
e.g.,
bevacizumab
(Avastin®),
epidermal
receptor
(EGFR)
cetuximab
(Erbitux®)
panitumumab
(Verbitix®).
However,
many
problems
are
still
being
experienced
these
treatments,
mainly
off-target
effects,
toxic
side
associated
therapeutic
failures
small
molecular
drugs
rapid
loss
efficacy
mAb
therapies.
Other
novel
delivery
strategies
continue
investigated,
ligand-based
targeting
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(10), P. 2252 - 2252
Published: Oct. 21, 2022
Central
nervous
system
(CNS)
diseases
threaten
the
health
of
people
all
over
world.
However,
due
to
structural
and
functional
particularities
brain
spinal
cord,
CNS-targeted
drug
development
is
rather
challenging.
Exosomes
are
small
cellular
vesicles
with
lipid
bilayers
that
can
be
secreted
by
almost
cells
play
important
roles
in
intercellular
communication.
The
advantages
low
immunogenicity,
ability
cross
blood-brain
barrier,
flexibility
encapsulation
make
them
stand
out
among
CNS
delivery
tools.
Herein,
we
reviewed
research
on
exosomes
past
decade
outlined
impact
loading
mode,
administration
route,
engineered
modification
targeting.
Finally,
highlighted
problems
prospects
as
Journal of Materials Chemistry B,
Journal Year:
2023,
Volume and Issue:
11(12), P. 2568 - 2613
Published: Jan. 1, 2023
In
the
past
few
years,
development
in
construction
and
architecture
of
graphene
based
nanocomplexes
has
dramatically
accelerated
use
nano-graphene
for
therapeutic
diagnostic
purposes,
fostering
a
new
area
nano-cancer
therapy.
